Can alpha-1 and beta-2 adrenergic receptor autoantibodies alter vascular and cardiac autonomic signaling?

Adrenergic-receptor autoantibodies are biologically plausible modifiers of vascular tone and cardiac autonomic signaling, but a positive antibody-binding result is not itself evidence of receptor stimulation or blockade.

Functional and clinical evidence

• α1-adrenergic receptor autoantibodies: Purified IgG from antibody-positive patients produced concentration-dependent contraction in isolated arteries. Prazosin prevented this response, supporting α1-receptor-specific activity. The same IgG increased mean arterial pressure in an animal model.
• β2-adrenergic receptor autoantibodies: Cell-based studies show receptor-specific activation of β2 signaling, including cAMP and β-arrestin pathways. In Graves’ disease, antibody detection and activation activity occurred in people with sinus tachycardia, supporting potential relevance to adrenergic rate regulation; this did not establish a specific relationship with atrial fibrillation.
• Human clinical causality remains uncertain. A controlled study reporting normal cardiovascular responses and no change after antibody removal weakens the inference that α1 autoantibodies are necessarily pathogenic in vivo.

Mechanistic interpretation

• Functional α1 antibodies may increase vascular smooth-muscle contraction and thereby influence blood pressure.
• Functional β2 antibodies may alter receptor signaling relevant to cardiac chronotropy and autonomic regulation. Effects may vary by antibody epitope, receptor conformation, signaling pathway measured, and experimental system.

Interpreting antibody tests

• ELISA and other binding assays establish recognition of the tested antigen—often an extracellular-loop peptide—not whether antibody binds the native receptor in a signaling-relevant conformation.
• They cannot distinguish agonism, antagonism, inverse agonism, or neutral binding. For example, ELISA-detected β2 antibodies have shown receptor-specific activation in some cell studies, whereas elevated antibody levels in some ME/CFS samples produced little or no β2-dependent cAMP response.
• Receptor-expressing functional assays are therefore required; antagonism specifically requires testing inhibition of an appropriate agonist-stimulated response.

Bottom line

• The claim is supported: these autoantibodies can have functional vascular or adrenergic signaling effects, but binding-assay positivity alone cannot determine their functional direction or clinical significance.